Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing the early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests, which leverage artificial intelligence, epigenetics, and genetics. The company's proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss.
This innovation comes at a critical time, as the cardiovascular disease market is projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050. By detecting disease earlier and more accurately, Cardio Diagnostics aims to reduce the burden of cardiovascular disease and improve patient outcomes.
The company has strengthened its commercialization efforts by securing finalized CMS reimbursement rates and dedicated CPT laboratory codes. These milestones facilitate broader adoption by healthcare providers. Additionally, Cardio Diagnostics has expanded U.S. provider partnerships and launched its first international expansion in India, signaling growing confidence in its technology.
Cardio Diagnostics' approach addresses a significant gap in current diagnostic methods. Traditional tools often miss nonobstructive coronary artery disease, which can still lead to heart attacks. The company's tests provide a more comprehensive risk assessment, potentially identifying at-risk patients earlier.
The company's position is both scientifically grounded and commercially actionable. Its proprietary platform, combined with reimbursement milestones and growing provider adoption, places it at the forefront of precision cardiovascular medicine. For more information about Cardio Diagnostics, visit cdio.ai.
To view the full article, visit https://nnw.fm/9LJ2r.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.
